BioSpecifics Technologies Corp.
BSTC
BSTC was delisted on the 1st of December, 2020.
114 hedge funds and large institutions have $247M invested in BioSpecifics Technologies Corp. in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 34 reducing their positions, and 12 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 34
0% more funds holding
Funds holding: 114 → 114 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
5% less capital invested
Capital invested by funds: $259M → $247M (-$12.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$9.38M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.64M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.76M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$2.17M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.66M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$2.49M |
| 3 |
MCM
Matarin Capital Management
New York
|
-$2.38M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.99M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$1.98M |
BSTC Hedge Fund Activity: Q3 2019 in Review
114 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q3 2019, worth a combined $247M — down 4.7% from $259M a quarter earlier.
Fund positioning in BSTC was balanced in Q3 2019: 12 funds opened new positions, 12 closed out, 40 added to existing stakes and 34 trimmed.
The largest buyer was Royce & Associates, adding an estimated $9.38M. The largest seller was Millennium Management, cutting an estimated $4.66M.
- 114 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $247M of BioSpecifics Technologies Corp. stock for Q3 2019, down 4.7% quarter-over-quarter.
- 12 funds opened new BioSpecifics Technologies Corp. positions in Q3 2019 and 12 closed out, a net change of 0 holders.
- The largest BioSpecifics Technologies Corp. buyer in Q3 2019 was Royce & Associates, an estimated $9.38M added.
- The largest BioSpecifics Technologies Corp. seller in Q3 2019 was Millennium Management, an estimated $4.66M sold.
Based on aggregated 13F filings for Q3 2019.